Nanoviricides, Inc. · AMEX:NNVC
Nanoviricides — Biotech Showcase 2023
30 slides from Nanoviricides's conference presentation, Jan 9, 2023
Slide 1: Pan-coronavirus Broad-spectrum Nanomedicines NV-CoV-2 and NV-CoV-2-R
“Bind-Encapsulate-Destroy” Stock Symbol: NNVC (NYSE American) Pan-coronavirus Broad-spectrum Nanomedicines NV-CoV-2 and NV-CoV-2-R to Attack the SARS-CoV-2 Virus and its Variants in the Global Pandemic Corporate Presentation at the Biotech Showcase 2023 January 9, 2023 Hilton San Fransisco, Union Sq
Slide 2: Disclosure Statement
Disclosure Statement NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC). This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only. NanoViricides, Inc.(www.nanoviricide
Slide 3: Presentation Layout
Presentation Layout NanoViricides Clinical-Ready Assets NanoViricides Platform Technology Assets COVID-19 Pandemic Overview Developing Drugs that Virus May Not Escape due to Mutations SARS-CoV-2 Therapeutics Development Strategy and Status Lead Drug Candidates Against SARS-CoV-2 Industry-Leading Pla
Slide 4: NanoViricides Drug Products: Clinical-Ready Assets
NanoViricides Drug Products : Clinical-Ready Assets NV-CoV-2: Treatment of COVID-19 and certain cases of long COVID Ready for human Clinical Trials API NV-387, Various NV-CoV-2 Drug Product Formulations Broad-Spectrum, Pan-coronavirus Drug - “Resistance is Futile" Highly Effective and Extremely Safe
Slide 5: NanoViricides Technology Platforms
NanoViricides Technology Platforms NanoViricides Technology Platform for Drug Encapsulation: The nanoviricides technology platform is proven to be capable of encapsulating and thereby protecting a number of APIs improving their PK/PD and bioactivity Enables long acting acute timeframe (~ 24 - 72 hou
Slide 6: COVID-19 Pandemic in Third Year is Not Done Yet
COVID-19 Pandemic in Third Year is Not Done Yet Variants Fuel New Waves, Since ca. December 2019 No End in Sight Regarding New Variants Appearing in the Future Major Waves - Alpha, Delta, Omicron - Omicron - Omicron! Waves of Infection Cycling Around the Globe Entering Omicron XBB.1, XBB.1.5, BQ1, B
Slide 7: SARS-CoV-2 Virus is On Course to Become Endemic
SARS-CoV-2 Virus is On Course to Become Endemic Variants Will Continue to Evolve, Resistant to Vaccines and Antibodies Vaccines Have Not Provided Long Term Immunity An Effective Drug is Limitations of Antibody Therapies the Weapon Needed for Closing the No “Curative Immunity” COVID-19 Threat from Va
Slide 8: Current Scenario - SARS-CoV-2 Therapeutics
Current Scenario - SARS-CoV-2 Therapeutics Remdesivir is the Only Approved Drug for Severe, Hospitalized Cases Its Effectiveness is Limited by (a) Metabolism and (b) Toxicity Antibodies- No Active Antibodies Remain As of Now! All EUAs Revoked!! ORAL DRUGS so far EUA Only for Mild to Moderate Disease
Slide 9: Traditional Drug Development Methodologies Have Not Resulted in an Effective Drug
Traditional Drug Development Methodologies Have Not Resulted in an Effective Drug Against SARS-CoV-2 Variants NanoViricides is Different Our Novel Approach Has Already ENABLED : Variant-Proof Drugs Normal Virus LifeCycle Blocking the Complete Viral LifeCycle Virus Abundant Particle Progeny Without R
Slide 10: TWO COVID Drug Candidates in Development
NanoViricides - TWO COVID Drug Candidates in Development NV-CoV-2 : A nanoviricide® designed to attack the virus and destroy it, thus Blocking Re-Infection NV-CoV-2-R : Amplifies the Power of Remdesivir to Block Replication, and Adds it to the Power of NV-CoV-2 to Block ReInfection NV-CoV-2 Has Show
Slide 11: NV-CoV-2 and NV-CoV-2-R Superior to Remdesivir in Lethal Infection Studies
Both NV-CoV-2 and NV-CoV-2-R Found to be Substantially Superior to Remdesivir in Lethal SARS-Emulating Coronavirus Infection Animal Studies Lethal SARS-Emulating Animal Study Demonstrated Strong Efficacy Body Weight Loss Lung General Survival, Treatment (Less is Better), Histopathology Organ Days Da
Slide 12: NV-CoV-2 Demonstrated Broad-Spectrum, Pan-Coronavirus Activity
NV-CoV-2 Demonstrated Broad-Spectrum, Pan-Coronavirus Activity Broad-Spectrum, Pan-Coronavirus Activity: NV-CoV-2 Has Shown Strong Effectiveness in Animal Models that Used ACE2-Binding Coronavirus Causing Lethal Lung Infection Emulating SARS-CoV-2 Clinical Disease Effective Against All Tested, Unrel
Slide 13: NV-CoV-2 is Ready for Clinical Trials
NV-CoV-2 is Ready for Clinical Trials Pre-Clinical Safety/Toxicology: Extremely Safe in Animal Studies Primates, Rats, Mice Orally Effective Formulations Manufactured NV-CoV-2 Oral “Gummies” An Easy to Use, Soft-candy-like Formulation with fixed dose for Children and Adults NV-CoV-2 Oral Syrup Easy
Slide 14: NV-CoV-2 is Ready for Clinical Trials
NV-CoV-2 is Ready for Clinical Trials NV-CoV-2 cGMP-Compliant Manufacture is Established at NanoViricides cGMP-Capable Manufacturing Facility in Shelton, CT Process Development, Quality Assurance, etc. for Drug Substance and for Drug Products Completed Process Scale-Up Completed Up to ~ 5 Kg Drug Su
Slide 15: Technology Platform Defines A Novel Paradigm in Antiviral Medicines
NanoViricides Technology Platform Defines A Novel Paradigm in Antiviral Medicines Enables NV-CoV-2, NV-CoV-2, NV-CoV-2-R Nanomachines A “NanoViricide” is a Nanomachine Designed to Attack the Virus Particle 1. Bind the Virus Particle (Multiple-Point, “NanoVelcro” Effect) 2. Engulf the Virus Particle
Slide 16: A nanoviricide is a Cell Mimic
Novel Platform Technology: A nanoviricide® is a Cell Mimic Cell Viral Resistance to the Nanoviricide Drug is Unlikely i cial r y r tif imic A -M because Even as the Virus Mutates, B i o It Still Binds to the Same Cell Surface Receptor(s), in the Same Fashion HIV Particle binding to a Cell via CD4 an
Slide 17: Technology Platform Enables Complete Cure of Non-Integrating Viruses
NanoViricides Technology Platform Enables Complete Cure of Non-Integrating Viruses Effectively Encapsulate Other APIs Break “Lipinski Barrier” Deliver Encapsulated APIs to Virus-Infected Cells, Sparing Normal Cells Minimize Guest API Toxicity Minimize Guest API Metabolism Improve Guest API Circulati
Slide 18: NV-CoV-2-R is Designed to Block the SARS-CoV-2 Virus Lifecycle Completely
NV-CoV-2-R is Designed to Block the SARS-CoV-2 Virus Lifecycle Completely - A Potential Cure DUAL MODE ATTACK - Possibly the Only Drug in Development to do this! Its NV-CoV-2 Component Nanomachine Blocks the Virus Re-infection Cycle Block Virus Attack from Virus Particles in Fluids Outside of Cells
Slide 19: Nanoviricides Dismantling MCMV Virus Particle
Nanoviricides Dismantling MCMV Virus Particle Control Treated A MCMV Virus Particle Containing Multiple Capsids Virus Dismantled; Capsids Spilling Out A: intermediate state; C: total dismantling C © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-mkt: NNVC) © All Rights Res
Slide 20: Highly Effective, Variant-Proof, Safe NanoViricide Drug Candidates
Highly Effective, Variant-Proof, Safe NanoViricide Drug Candidates Both NV-CoV-2 and NV-CoV-2-R Have Demonstrated: Strong Effectiveness Against: Therefore: + SARS-CoV-2 Pseudovirions Both of These Drugs Should (Uses ACE2) Remain Effective Against All + Human Coronavirus NL-63 Variants of SARS-CoV-2
Slide 21: Platform Technology with Broad Drug Pipeline
NanoViricides Platform Technology with Broad Drug Pipeline Advanced Stage - IND-Enabled NV-CoV-2, NV-CoV-2-R for ALL Coronavirus Infections NV-HHV-1 Skin Cream for Treatment of Shingles Rash Pre-Clinical, Ready to Advance HSV-1, HSV-2 (Pre-clinical) Local Treatment - Skin Cream Systemic Treatment -
Slide 22: Investment Thesis: NanoViricides Valuation
Investment Thesis: NanoViricides Valuation Company Founded and taken public (reverse shell merger) in 2005 - Platform Technologies Licensed from TheraCour Pharma, Inc. Market Cap Historically Around $100~150M Uplisted to NYSE-American in September 2013 Moved to Integrated cGMP Manufacturing & R&D Fa
Slide 23: Both Candidates Superior to Remdesivir in Coronavirus Animal Studies
Both NV-CoV-2 and NV-CoV-2-R Are Substantially Superior to Remdesivir in Coronavirus Infection Animal Studies NV-CoV-2 NV-CoV-2 By Itself is A Clinical Drug Candidate with Strong and Broad-Spectrum Efficacy Affords faster Clinical Development than NV-CoV-2-R NV-CoV-2-R Strong effect of NV-CoV-2-R is
Slide 24: GLP Safety Toxicology Studies of NV-CoV-2 Completed
GLP Safety Toxicology Studies of NV-CoV-2 Completed No Evidence of Adverse Effects GLP neuro-pulmonary safety pharmacology study in rats concluded: The intravenous administration of NV-CoV-2 at doses of 25, 50 and 100 mg/kg did not affect respiratory function in rats GLP cardiovascular function stud
Slide 25: Non-GLP Safety Toxicology Studies Completed
Non-GLP Safety Toxicology Studies of Both NV-CoV-2 and NV-CoV-2-R Completed Strong Safety at Very High Dosage Levels Rats dosed at up to 562 mg/kg body weight by tail vein intravenous injection on Days 0,1,3,5,7,9 for a total of 3,375mg/kg dose of NV-CoV-2 showed no side effects Rats dosed at up to
Slide 26: Unique Drug Developer with Own cGMP-Capable Manufacturing
NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability Clinical Product Supply Capability for Mostly All of Our Nanoviricides Significant Time and Cost Savings Potential for Manufacturing Commercial Product - Market Entry & Early Revenues Nanomedicines Ch
Slide 27: Recap
Recap “Resistance is Futile” - Antiviral Nanomachines Designed to Destroy Viruses Despite Viral Mutations Broad and Deep Pipeline based on Platform Technology Next Generation NanoViricides (with Encapsulated Additional Action) Already in Development In-house cGMP Manufacture Enabling Early Commercia
Slide 28: Strong Executive Team
Strong Executive Team Anil R. Diwan, PhD Randall W. Barton, PhD President & Exec. Chairman CSO and Acting CRO Co-Founder 30+ Years of Pharmaceutical Industry Experience in Drug Led Uplisting to NYSE-American Exchange in 2013 Discovery and Pre-clinical Regulatory Development Raised $65M Former Direct
Slide 29: Board of Directors
Board of Directors Anil R. Diwan, PhD Mak Jawadekar, PhD ✔ President & Exec. Chairman 35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Co-Founder, Led Uplisting to NYSE-Amer
Slide 30: The End
The End © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 30